SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-050567
Filing Date
2024-04-23
Accepted
2024-04-23 16:00:36
Documents
13
Period of Report
2024-04-22
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2411028d2_8k.htm   iXBRL 8-K 27825
  Complete submission text file 0001104659-24-050567.txt   204293

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rnaz-20240422.xsd EX-101.SCH 3054
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rnaz-20240422_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rnaz-20240422_pre.xml EX-101.PRE 22385
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2411028d2_8k_htm.xml XML 3795
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

IRS No.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40363 | Film No.: 24864742
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)